Curanex Pharmaceuticals Inc(CURX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 30 at 7:30 PM ET (Korea 10/1 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -7.38 | Insider Own | 61.35% | Shs Outstand | 1.4M | Perf Week | 11.96% |
| Market Cap | 0.01B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 0.6M | Perf Month | 16.51% |
| Enterprise Value | 0.01B | PEG | - | EPS next Q | - | Inst Own | 1.07% | Short Float | 0.46% | Perf Quarter | -8.64% |
| Income | -0.01B | P/S | - | EPS this Y | - | Inst Trans | 1.17% | Short Ratio | 0.17 | Perf Half Y | -51.01% |
| Sales | 0.00B | P/B | 1.48 | EPS next 5Y | - | ROA | -357.22% | Short Interest | 0.00M | Perf YTD | -24.23% |
| Book/sh | 3.38 | P/C | 2.67 | EPS past 3/5Y | -1369.89% - | ROE | -411.08% | 52W High | -70.41% ($16.93) | Perf Year | -65.21% |
| Cash/sh | 1.88 | P/FCF | - | Sales past 3/5Y | - | ROIC | -210.65% | 52W Low | 40.1% ($3.58) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -2256.41% | Gross Margin | - | Volatility(W/M) | 8.17% 11.82% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.46 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 45.95 | EPS Q/Q | -5246.54% | Profit Margin | - | RSI (14) | 58.6 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 45.95 | Sales Q/Q | - | SMA20 | 8.87% ($4.6) | Beta | -2.82 | Target Price | - |
| Payout | - | Debt/Eq | 0.06 | Earnings | - | SMA50 | 13.53% ($4.41) | Rel Volume | 0.07 | Prev Close | $4.97 |
| Employees | 6 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | -22.5% ($6.46) | Avg Volume(3M) | 0.02M | Price | $5.01 |
| IPO | 2025/8/26 | Option/Short | No/Yes | Trades | 67 | Volume | 1,186 | Change | 0.8% |
🌿 Quronex Pharmaceuticals is a pre-clinical-stage biotech company developing single-component, plant-derived anti-inflammatory drug candidates. Its lead candidate, Phyto-N, has demonstrated efficacy in animal models of multiple inflammatory diseases, including ulcerative colitis, atopic dermatitis, diabetes, non-alcoholic fatty liver disease, and gout. The company became listed via a Nasdaq IPO in August 2025 and is preparing to initiate a Phase 1 clinical trial in Australia, positioning it as a newly listed micro-cap biotech.
Over the past 1 year, on the lower side
70% below its 1-year high.
Traded less than usual That is 7% of its average volume.
CURX has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 1.1%.
Tap to view numbers
It ranks #528 of 592 in the industry
Based on market cap of $8M.
ENSC#526 Ensysce Biosciences Inc $8M PER - 
SNGX#527 Soligenix Inc $8M PER - CURX#528 Curanex Pharmaceuticals Inc $8M PER - 
CNSP#529 Cns Pharmaceuticals Inc $8M PER - 
XCUR#530 Exicure Inc $8M PER - 
FAQ
What kind of company is CURX?
CURX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of CURX?
The market cap of CURX is approximately $8M, ranking 5,562 within its sector.
What is the 52-week high and low for CURX?
CURX has recorded a 52-week high of $16.93 and a low of $3.58.
